This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-22 and is reviewed periodically as new material appears.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
It is not possible to determine the structure of a protein with H/D exchange other than neutron crystallography nor is it possible to define secondary structural elements. The reasons for this are related to the way in which protein structure slows exchange. Exchange rates are a function of two parameters: solvent accessibility and hydrogen bonding. Thus an amide which is part of an intramolecular hydrogen bond will exchange slowly if at all, while an amide on the surface of protein hydrogen bonded to water will exchange rapidly. Amides buried from the solvent but not hydrogen bonded may also have very slow exchange rates. Because both solvent accessibility and hydrogen bonding contribute to the rate of exchange, it becomes difficult to attribute a given exchange rate to a structural element without crystallography or NMR structural data. H–D exchange has been used to characterize the folding pathway of proteins, by refolding the protein under exchange conditions. In a forward exchange experiment (H to D), a pulse of deuterium is added after various amounts of refolding time. The parts of the structure that form rapidly will be protected and thus not exchanged, whereas areas that fold late in the pathway will be exposed to the exchange for longer periods of time. Thus H/D exchange can be used to determine the sequence of various folding events. Factors determining the time resolution of this approach are the efficiency of mixing and how quickly the quench can be performed after the labeling.
The acetylation at position 3 and the conversion into a dihydromorphinone class semisynthetic (at position 14 on the morphine carbon skeleton) allows for the drug to more rapidly enter the central nervous system in greater quantity where it is de-acetylated into hydromorphone, and also converted by other processes into hydromorphinol, morphine and various other active and inactive substances; it therefore simultaneously takes advantage of two methods of increasing the effectiveness of morphine and its derivatives, those being catalytic hydrogenation (codeine into hydrocodone) and esterification (morphine into diamorphine, nicomorphine &c) in a manner not unlike to that of dihydrodiacetylmorphine.
Small but significant increases in hemoglobin and hematocrit, and small but significant decreases in fasting blood glucose, insulin levels, and insulin resistance, have been observed with enobosarm at 3 mg/day. In small short-term (3-month) clinical trials in healthy elderly or postmenopausal women, enobosarm at doses ranging from 0.1 to 3 mg/day had mixed effects on sebum production and did not increase body hair growth or cause hirsutism. These effects are measures of androgenic action in skin and hair follicles. In the first study, at doses of 0.1 to 3 mg/day, there were no significant changes relative to placebo in sebum tape scores with enobosarm and there were no consistent increases in Ferriman–Gallwey score, with most women having no change in score or a decreased score and only one having an increase in score. In the second study, which employed 3 mg/day enobosarm, there was a significant 1.25-fold increase in sebum production from baseline and a significant 1.5-fold increase in sebum production relative to placebo. No differences in sebaceous gland volume were apparent upon histological examination in this study. At doses ranging from 0.1 to 18 mg/day in clinical trials, enobosarm has been associated with elevated liver enzymes in subsets of individuals. Rates of elevated liver enzymes or of elevated alanine aminotransferase (ALT) levels have ranged from 0.6% to 33% in these trials. Liver enzyme elevations with enobosarm are often transient and resolve spontaneously.
=== Chemical labeling === Chemical labeling or the use of chemical tags utilizes the interaction between a small molecule and a specific genetic amino acid sequence. Chemical labeling is sometimes used as an alternative for GFP. Synthetic proteins that function as fluorescent probes are smaller than GFP's, and therefore can function as probes in a wider variety of situations. Moreover, they offer a wider range of colors and photochemical properties. With recent advancements in chemical labeling, Chemical tags are preferred over fluorescent proteins due to the architectural and size limitations of the fluorescent protein's characteristic β-barrel. Alterations of fluorescent proteins would lead to loss of fluorescent properties.
Sources: en.wikipedia.org
== History == Colistin was first isolated in Japan in 1949 by Y. Koyama, from a flask of fermenting Bacillus polymyxa var. colistinus, and became available for clinical use in 1959. Colistimethate sodium, a less toxic prodrug, became available for injection in 1959. In the 1980s, polymyxin use was widely discontinued because of nephro- and neurotoxicity. As multi-drug resistant bacteria became more prevalent in the 1990s, colistin started to get a second look as an emergency solution, in spite of toxicity. Colistin has also been used in agriculture, particularly in China from the 1980s onwards. Chinese production for agriculture exceeded 2700 tons in 2015. China banned colistin use for livestock growth promotion in 2016.
=== January === 1 January – In his New Year address, Archbishop of Canterbury Justin Welby urges politicians to treat their opponents as human beings rather than enemies. Secretary of State for Defence Grant Shapps says that British forces are ready to act against Houthi rebels targeting cargo ships in the Red Sea. Writing on X, Doug Barrowman, husband of Michelle, Baroness Mone, said it "suits the agenda" of ministers to "scapegoat" him and his wife as a means of distracting from government "incompetence" at failing to procure personal protective equipment during the COVID-19 pandemic. 2 January – The Home Office says it has fulfilled a pledge to clear a "legacy" backlog of 92,000 asylum applications lodged before July 2022. But after it subsequently emerges that over 4,000 cases are still waiting for a decision, the Office for Statistics Regulation (OSR) announces an examination of the figures the next day. 3 January – Sir Ed Davey, leader of the Liberal Democrats, launches the party's election campaign by targeting constituencies with Conservative MPs. Former chancellor of the exchequer Nadhim Zahawi makes a guest appearance in the ITV drama Mr Bates vs The Post Office as himself, questioning Post Office chief executive Paula Vennells in a 2015 House of Commons committee inquiry into the Horizon computer system. Richard Tice, leader of Reform UK, rules out a pact with the Conservative Party at the next general election. 4 January – Prime Minister Rishi Sunak says his "working assumption" is that the general election will take place in the second half of this year.
There has been recent speculation that the increase in such carbohydrates since sucrose (table sugar—half glucose and half fructose) became available in quantity after about 1700 with the discovery of a practical source (sugar cane), accounts for some of the diseases of civilization, including diabetes. Fructose had been quite rare in human diet until that time. Dietary fructose also characteristically causes alterations in blood lipid profiles, probably by changing liver operations. Cardiologist a physician with special training for treating heart and circulatory problems. Cardiovascular pertaining to the heart and vascular system (blood vessels). Carpal tunnel syndrome irritation and swelling of one or more of the nerves in the carpal tunnel in the wrist. Effects range from considerable pain to loss of strength or muscle control. The cause is thought to be mechanical, as in repetitive motion of the wrist joint as in typing while in inappropriate wrist positions. Cataract clouding of the transparent protein in the lens of the eye. A certain amount of this clouding occurs naturally during life. The elderly do not, therefore see quite the same way as they used to since there is a slight yellowish cast in the clouded lens. Diabetics have an increased risk for cataract since high levels of glucose cause reactions with assorted proteins, including those in the lens; many of the reaction products are not optically clear, nor pack in the same way, thus altering the shape of the lens.
Sources: en.wikipedia.org
=== Live data === Files that are actively being updated present a challenge to back up. One way to back up live data is to temporarily quiesce them (e.g., close all files), take a "snapshot", and then resume live operations. At this point the snapshot can be backed up through normal methods. A snapshot is an instantaneous function of some filesystems that presents a copy of the filesystem as if it were frozen at a specific point in time, often by a copy-on-write mechanism. Snapshotting a file while it is being changed results in a corrupted file that is unusable. This is also the case across interrelated files, as may be found in a conventional database or in applications such as Microsoft Exchange Server. The term fuzzy backup can be used to describe a backup of live data that looks like it ran correctly, but does not represent the state of the data at a single point in time. Backup options for data files that cannot be or are not quiesced include:
=== Hydrogenation === Hydrogenation is achieved by introducing hydrogen to the unsaturated compounds under high pressure in the presence of heterogeneous catalysts, such as finely divided nickel. This reaction converts benzene into cyclohexane. Benzene derivatives are also converted into their respective saturated equivalents. Whereas alkenes can be hydrogenated near room temperatures, benzene and its derivatives are more reluctant substrates, requiring temperatures exceeding 100 °C for hydrogenation to occur. This reaction is practiced on an industrial scale. Typically, benzene is fully saturated into cyclohexane during hydrogenation. However, with the right conditions, benzene can be partially-hydrogenated to give cyclohexene or cyclohexadienes. A similar reaction is the Birch reduction, which is a non-catalytic process that converts benzene into cyclohexadiene.
=== Lipid-based nanoparticles === Lipid-based nanoparticles (LNP) can deliver molecules with low toxicity and controlled release. Liposomes, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and nanoemulsions are examples. Liposomes are made up of phospholipids forming spherical vesicles. This property enables liposomes to exhibit high biocompatibility and biodegradability. Studies report potential application of liposomes to treat brain diseases due to increased retention and absorption in nasal cavity, and high brain biodistribution. A previous study developed a cationic liposome loaded with mRNA and green fluorescent protein (GFP). Intranasal delivery of this formulation in murine models demonstrated high brain biodistribution and expression of mRNA-GFP. Solid lipid nanoparticles (SLNs) are made up of solid lipids forming a matrix and stabilized by surfactants. They exhibit high physical stability and remain in solid state at different temperatures. Sometimes burst release may occur due to rigidity and less flexibility in shape. Nanostructured lipid carriers (NLC) are synthesized by a mixture of solid and aqueous lipids. NLC's are developed from SLNs, thus referred to as second generation LNPs. Intranasal administration of NLC loaded with curcumin (CRM) increased biodistribution and concentration in brain after emerging as a potential system for brain cancer. Small colloidal systems made of micelles containing oil, aqueous phases, and emulsifiers are called nanoemulsions.
Unlike reference materials, working standards are typically not calibrated across multiple analytical facilities and the accepted δ value measured in a given laboratory could reflect bias specific to a single instrument. However, within a single analytical facility this bias can be removed during data reduction. Because each laboratory defines unique working standards the primary, calibration, and reference materials are long-lived while still ensuring that the isotopic composition of unknown samples can be compared across laboratories.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.